Clinical Trial Update: Study to Evaluate the Effect of Bimosiamose on Ozone Induced Sputum Neutrophilia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Bimosiamose for COPD, assessing its effect on ozone-induced sputum neutrophilia, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Bimosiamose (bimosiamose)

Snippet

Sponsor: Revotar Biopharmaceuticals AG | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Status: COMPLETED